Status:
COMPLETED
Maribavir for Prevention of CMV After Stem Cell Transplants
Lead Sponsor:
Shire
Conditions:
Cytomegalovirus Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy. Maribavir is a new oral anti-CMV drug wi...
Eligibility Criteria
Inclusion
- Allogeneic stem cell transplant recipient
- Recipient CMV seropositive
- Have transplant engraftment
- Able to swallow tablets
Exclusion
- CMV organ disease
- HIV infection
- Use of other anti-CMV therapy post-transplant
Key Trial Info
Start Date :
October 28 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 5 2006
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT00223925
Start Date
October 28 2004
End Date
April 5 2006
Last Update
May 13 2021
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope Medical Center
Duarte, California, United States
2
UCLA Medical Center
Los Angeles, California, United States
3
Loyola University
Maywood, Illinois, United States
4
Tufts-New England Medical Center
Boston, Massachusetts, United States